Alembic Pharma receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%
Mumbai, October 19th, 2026: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Ciprodex…
